Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Intraoperative radiotherapy for glioblastoma: an international pooled analysis.

Sarria GR, Sperk E, Han X, Sarria GJ, Wenz F, Brehmer S, Fu B, Min S, Zhang H, Qin S, Qiu X, Hänggi D, Abo-Madyan Y, Martinez D, Cabrera C, Giordano FA.

Radiother Oncol. 2019 Oct 16. pii: S0167-8140(19)33112-3. doi: 10.1016/j.radonc.2019.09.023. [Epub ahead of print]

2.

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial.

Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F.

Neurosurgery. 2019 Jan 1;84(1):41-49. doi: 10.1093/neuros/nyy018.

PMID:
29528443
3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients.

Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF.

J Neurosurg. 2013 Apr;118(4):786-98. doi: 10.3171/2012.10.JNS112268. Epub 2012 Nov 23.

PMID:
23176331
5.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

6.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
7.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
8.

Intraoperative radiotherapy (IORT) for breast cancer using the Intrabeam system.

Kraus-Tiefenbacher U, Scheda A, Steil V, Hermann B, Kehrer T, Bauer L, Melchert F, Wenz F.

Tumori. 2005 Jul-Aug;91(4):339-45.

PMID:
16277101
9.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
10.

Clinicoradiological features and surgical outcomes of primary intracranial medulloepitheliomas: a single-center experience and pooled analysis of individual patient data.

Li D, Hao SY, Wang L, Li GL, Wang JM, Wu Z, Zhang LW, Zhang JT, Jia W.

J Neurosurg. 2018 Jul 1:1-15. doi: 10.3171/2018.1.JNS172509. [Epub ahead of print]

PMID:
29979121
11.

Cerebellar glioblastoma: a retrospective review of 21 patients at a single institution.

Tsung AJ, Prabhu SS, Lei X, Chern JJ, Benjamin Bekele N, Shonka NA.

J Neurooncol. 2011 Dec;105(3):555-62. doi: 10.1007/s11060-011-0617-2. Epub 2011 Jun 4. Review.

PMID:
21643841
12.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203. doi: 10.1016/j.ijrobp.2018.01.001. Epub 2018 Jan 6. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1289.

13.

Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma.

Nitta M, Muragaki Y, Maruyama T, Iseki H, Komori T, Ikuta S, Saito T, Yasuda T, Hosono J, Okamoto S, Koriyama S, Kawamata T.

J Neurosurg. 2018 Dec 7:1-8. doi: 10.3171/2018.7.JNS18422. [Epub ahead of print]

PMID:
30544336
14.

Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery.

Kraus-Tiefenbacher U, Bauer L, Scheda A, Fleckenstein K, Keller A, Herskind C, Steil V, Melchert F, Wenz F.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):377-81. Epub 2006 Aug 2.

PMID:
16887294
15.

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.

PMID:
25768833
16.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
17.

Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, Upadhyay AD, Julka PK, Sharma D, Rath GK.

J Neurooncol. 2018 Oct;140(1):75-82. doi: 10.1007/s11060-018-2932-3. Epub 2018 Jun 23.

PMID:
29936695
18.

The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer.

Susko M, Lee J, Salama J, Thomas S, Uronis H, Hsu D, Migaly J, Willett C, Czito B, Palta M.

Ann Surg Oncol. 2016 Oct;23(11):3609-3615. doi: 10.1245/s10434-016-5250-z. Epub 2016 May 11.

PMID:
27169769
19.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

20.

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7.

PMID:
11163499

Supplemental Content

Support Center